Taro receives FDA approval for skin cancer generic
HAWTHORNE, N.Y. The Food and Drug Administration has approved Taro Pharmaceutical Industries’ generic version of a drug for treating skin cancer, Taro announced Monday.
The FDA approved Taro’s fluorouracil cream in the 5% strength. The drug is used to treat superficial basal cell carcinoma and multiple actinic or solar keratosis.
Fluorouracil is a generic version of Valeant Pharmaceuticals’ Efudex, which had sales of $70 million in 2009, according to industry sources.
McKesson named ‘World’s Most Admired’ by Fortune
SAN FRANCISCO A healthcare services and information technology company was ranked among the “World’s Most Admired” in an annual survey conducted by Fortune magazine and the Hay Group.
Fortune’s “World’s Most Admired” award measures corporate reputation and performance against nine key attributes: innovation, people management, use of corporate assets, social responsibility, quality of management, financial soundness, long-term investment, quality of products and services and global competitiveness. McKesson ranked No. 1 in all nine categories for the wholesale healthcare sector.
“At McKesson, corporate social responsibility principles are embedded within our mission to help our customers improve patients’ lives,” said John Hammergren, McKesson chairman and CEO. “As we continue to focus on making healthcare safer, more efficient, and less expensive we’re proud to be recognized as a leader among U.S. corporations.”
Coalition wants pharmacists to play role in drug safety programs
ALEXANDRIA, Va. Seventeen organizations and pharmacy chains hope the Food and Drug Administration will let pharmacists have a role in ensuring that patients use medication safely and effectively as it evaluates risk evaluation and mitigation strategies, also known as REMS.
The National Community Pharmacists Association, the American Pharmacists Association, Bartell Drugs, Shopko and 13 others sent a letter to the FDA about pharmacists’ ability to prevent adverse events and evaluate patients’ levels of understand via consultation.
“Studies have shown that community pharmacists providing face-to-face patient interactions may have a greater impact on patient behavior compared to other methods of service delivery,” the letter read. “Clearly, these services could be utilized to meet the goals of a REMS program.”